 | |
| Clinical data | |
|---|---|
| Trade names | Broncomenal, Deronyl, Finaten, Noleptan, Oleptan, Terion, Tosifar, Tussirama [1] |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard ( EPA) | |
| ECHA InfoCard | 100.038.135 |
| Chemical and physical data | |
| Formula | C21H24ClN3O3 |
| Molar mass | 401.89 g·mol−1 |
| 3D model ( JSmol) | |
| |
| |
Fominoben is an antitussive agent of the benzanilide class, formerly marketed under the name Noleptan. [2] It binds poorly to the sigma-1 receptor, a receptor activated by many other antitussives. [3] It is reported to have respiratory stimulant activity. [4] Other research has indicated it may be an agonist at the benzodiazepine site of the GABAA receptor. [5] It was introduced in Germany in 1973, in Italy in 1979, and in Japan in 1983. [6]
Adverse effects include appetite suppression, nausea, vomiting, insomnia, irritability, and hallucinations. Rarer side effects include somnolence, dizziness, dry mouth, blurred vision, and urticaria. [7]
References
- ^ Swiss Pharmaceutial Society, ed. (January 2000). Index Nominum 2000: International Drug Directory. Taylor & Francis. p. 470. ISBN 978-3-88763-075-1.
- ^ "FOMINOBEN". NCATS Inxight: Drugs. Retrieved March 25, 2021.
- ^ Musacchio JM, Klein M (June 1988). "Dextromethorphan binding sites in the guinea pig brain". Cellular and Molecular Neurobiology. 8 (2): 149–56. doi: 10.1007/BF00711241. PMID 3044591. S2CID 33844132.
- ^ Sasaki T, Sugiyama M, Sasaki H, Suzuki S, Takishima T (1985). "Effects of the antitussive fominoben (PB89) on hypoxia in chronic obstructive lung disease: comparison with dextromethorphan using a double-blind method". The Journal of International Medical Research. 13 (2): 96–101. doi: 10.1177/030006058501300204. PMID 3158563. S2CID 30176251.
- ^ Crawley JN, Blumstein LK, Baldino F (January 1984). "Anxiolytic-like properties of fominoben". European Journal of Pharmacology. 97 (3–4): 277–81. doi: 10.1016/0014-2999(84)90460-6. PMID 6142823.
- ^ William Andrew Publishing (22 October 2013). Pharmaceutical Manufacturing Encyclopedia. Elsevier. pp. 1705–7. ISBN 978-0-8155-1856-3.
- ^ Martín AV (2004). "Tratamiento sintomático de la tos y del resfriado común". Farmacología clínica y terapéutica médica. McGraw-Hill/Interamericana. p. 260. ISBN 9788448604271.
|
| |
| Clinical data | |
|---|---|
| Trade names | Broncomenal, Deronyl, Finaten, Noleptan, Oleptan, Terion, Tosifar, Tussirama [1] |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard ( EPA) | |
| ECHA InfoCard | 100.038.135 |
| Chemical and physical data | |
| Formula | C21H24ClN3O3 |
| Molar mass | 401.89 g·mol−1 |
| 3D model ( JSmol) | |
| |
| |
Fominoben is an antitussive agent of the benzanilide class, formerly marketed under the name Noleptan. [2] It binds poorly to the sigma-1 receptor, a receptor activated by many other antitussives. [3] It is reported to have respiratory stimulant activity. [4] Other research has indicated it may be an agonist at the benzodiazepine site of the GABAA receptor. [5] It was introduced in Germany in 1973, in Italy in 1979, and in Japan in 1983. [6]
Adverse effects include appetite suppression, nausea, vomiting, insomnia, irritability, and hallucinations. Rarer side effects include somnolence, dizziness, dry mouth, blurred vision, and urticaria. [7]
References
- ^ Swiss Pharmaceutial Society, ed. (January 2000). Index Nominum 2000: International Drug Directory. Taylor & Francis. p. 470. ISBN 978-3-88763-075-1.
- ^ "FOMINOBEN". NCATS Inxight: Drugs. Retrieved March 25, 2021.
- ^ Musacchio JM, Klein M (June 1988). "Dextromethorphan binding sites in the guinea pig brain". Cellular and Molecular Neurobiology. 8 (2): 149–56. doi: 10.1007/BF00711241. PMID 3044591. S2CID 33844132.
- ^ Sasaki T, Sugiyama M, Sasaki H, Suzuki S, Takishima T (1985). "Effects of the antitussive fominoben (PB89) on hypoxia in chronic obstructive lung disease: comparison with dextromethorphan using a double-blind method". The Journal of International Medical Research. 13 (2): 96–101. doi: 10.1177/030006058501300204. PMID 3158563. S2CID 30176251.
- ^ Crawley JN, Blumstein LK, Baldino F (January 1984). "Anxiolytic-like properties of fominoben". European Journal of Pharmacology. 97 (3–4): 277–81. doi: 10.1016/0014-2999(84)90460-6. PMID 6142823.
- ^ William Andrew Publishing (22 October 2013). Pharmaceutical Manufacturing Encyclopedia. Elsevier. pp. 1705–7. ISBN 978-0-8155-1856-3.
- ^ Martín AV (2004). "Tratamiento sintomático de la tos y del resfriado común". Farmacología clínica y terapéutica médica. McGraw-Hill/Interamericana. p. 260. ISBN 9788448604271.